Literature DB >> 26155404

HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer.

Yoshihiko Hirohashi1, Toshihiko Torigoe1, Tasuku Mariya2, Vitaly Kochin1, Tsuyoshi Saito3, Noriyuki Sato1.   

Abstract

Cytotoxic T lymphocytes (CTLs) recognize the human leukocyte antigen (HLA) class I and antigenic peptide complex, and they play a crucial role in cancer immunity. Our recent study revealed that HLA class I downregulation is related to poorer prognosis and a low level of intratumoral CTLs is associated with platinum resistance, indicating the significance of immunological surveillance.

Entities:  

Keywords:  CTL; CTL, cytotoxic T lymphocyte; HLA class I; HLA, human leukocyte antigen; MHC, major histocompatibility complex; TAA, tumor-associated antigen; ovarian cancer; platinum resistance

Year:  2015        PMID： 26155404      PMCID： PMC4485746          DOI： 10.1080/2162402X.2015.1005507

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

Review 3.  MHC class I antigens and immune surveillance in transformed cells.

Authors:  Natalia Aptsiauri; Teresa Cabrera; Angel Garcia-Lora; Miguel Angel Lopez-Nevot; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Int Rev Cytol       Date:  2007

4.  HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.

Authors:  Marco Vitale; Giuseppe Pelusi; Beatrice Taroni; Giuliana Gobbi; Cristina Micheloni; Rita Rezzani; Francesco Donato; Xinhui Wang; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

5.  Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.

Authors:  Tasuku Mariya; Yoshihiko Hirohashi; Toshihiko Torigoe; Takuya Asano; Takafumi Kuroda; Kazuyo Yasuda; Masahito Mizuuchi; Tomoko Sonoda; Tsuyoshi Saito; Noriyuki Sato
Journal:  Cancer Immunol Res       Date:  2014-10-16       Impact factor: 11.151

6.  Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.

Authors:  Phil Rolland; Suha Deen; Ian Scott; Lindy Durrant; Ian Spendlove
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

7.  Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.

Authors:  M Shehata; A Mukherjee; S Deen; A Al-Attar; L G Durrant; S Chan
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

Review 8.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Authors:  Liz Y Han; Mavis S Fletcher; Diana L Urbauer; Peter Mueller; Charles N Landen; Aparna A Kamat; Yvonne G Lin; William M Merritt; Whitney A Spannuth; Michael T Deavers; Koen De Geest; David M Gershenson; Susan K Lutgendorf; Soldano Ferrone; Anil K Sood
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 10.  Trial Watch: Peptide vaccines in cancer therapy.

Authors:  Fernando Aranda; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-11-04       Impact factor: 8.110
  10 in total
  5 in total

1.  MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy.

Authors:  Irene Romero; Cristina Garrido; Ignacio Algarra; Virginia Chamorro; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

2.  CAISMOV24, a new human low-grade serous ovarian carcinoma cell line.

Authors:  Rodrigo Fernandes da Silva; Daniela Maira Cardozo; Gisele Olinto Libanio Rodrigues; Caroline Natânia de Souza-Araújo; Natacha Azussa Migita; Liliana Aparecida Lucci de Angelo Andrade; Sophie Derchain; José Andrés Yunes; Fernando Guimarães
Journal:  BMC Cancer       Date:  2017-11-13       Impact factor: 4.430

3.  Identification of an immunotherapy-responsive molecular subtype of bladder cancer.

Authors:  Bic-Na Song; Seon-Kyu Kim; Jeong-Yeon Mun; Young-Deuk Choi; Sun-Hee Leem; In-Sun Chu
Journal:  EBioMedicine       Date:  2019-11-15       Impact factor: 8.143

4.  The role of Human leukocyte antigen class I on patient survival in Gastrointestinal cancers: a systematic review and meta- analysis.

Authors:  Hadis Najafimehr; Nastaran Hajizadeh; Ehsan Nazemalhosseini-Mojarad; Mohamad Amin Pourhoseingholi; Meghdad Abdollahpour-Alitappeh; Sara Ashtari; Mohammad Reza Zali
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

Review 5.  Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.

Authors:  Jayoung Kim; Peng Jin; Wei Yang; Wun Jae Kim
Journal:  Investig Clin Urol       Date:  2020-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.